<li>aspirin<p>aspirin increases levels of valproic acid by plasma protein binding competition. Use Caution/Monitor.</p></li><li>aspirin rectal<p>aspirin rectal increases levels of valproic acid by plasma protein binding competition. Use Caution/Monitor.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate increases levels of valproic acid by plasma protein binding competition. Use Caution/Monitor.</p></li><li>axitinib<p>valproic acid increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>blinatumomab<p>blinatumomab increases levels of valproic acid by decreasing metabolism. Modify Therapy/Monitor Closely. Treatment initiation causes transient release of cytokines that may suppress CYP450 enzymes; highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the 2nd cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index.</p></li><li>brodalumab<p>brodalumab, valproic acid. Other (see comment). Use Caution/Monitor. 
Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, brodalumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of brodalumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.</p></li><li>carbamazepine<p>valproic acid will increase the level or effect of carbamazepine by  Mechanism: decreasing metabolism. Use Caution/Monitor. Valproic acid may increase or decrease carbamazepine levels.<span><br><br></span>carbamazepine decreases levels of valproic acid by increasing metabolism. Use Caution/Monitor.</p></li><li>carvedilol<p>valproic acid will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>cholestyramine<p>cholestyramine decreases levels of valproic acid by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>dronabinol<p>dronabinol increases levels of valproic acid by plasma protein binding competition. Modify Therapy/Monitor Closely. Dronabinol is highly bound to plasma proteins and may displace and increase the free fraction of other concomitantly administered highly protein-bound drugs. This has not been confirmed in vivo. Caution with narrow therapeutic index drugs that are highly protein bound when initiating or increasing the dose of dronabinol.</p></li><li>dulaglutide<p>dulaglutide, valproic acid. Other (see comment). Use Caution/Monitor. 
Comment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index.</p></li><li>dupilumab<p>dupilumab, valproic acid. Other (see comment). Use Caution/Monitor. 
Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, dupilumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of dupilumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.</p></li><li>ethotoin<p>valproic acid will increase the level or effect of ethotoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>etravirine<p>valproic acid will increase the level or effect of etravirine by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>flibanserin<p>valproic acid will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.</p></li><li>fosphenytoin<p>valproic acid will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>glycerol phenylbutyrate<p>valproic acid decreases effects of glycerol phenylbutyrate by Other (see comment). Use Caution/Monitor. 
Comment: Valproic acid may induce hyperammonemia; monitor ammonia levels closely when coadministered with glycerol phenylbutyrate.</p></li><li>guanfacine<p>guanfacine increases levels of valproic acid by unknown mechanism. Use Caution/Monitor. Both 3-hydroxy guanfacine (metabolite) and valproic acid are metabolized by glucuronidation, possibly resulting in competitive inhibition.</p></li><li>ivacaftor<p>valproic acid increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors .</p></li><li>ixekizumab<p>ixekizumab, valproic acid. Other (see comment). Use Caution/Monitor. 
Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, ixekizumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of ixekizumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.</p></li><li>lamotrigine<p>valproic acid increases levels of lamotrigine by decreasing hepatic clearance. Use Caution/Monitor.</p></li><li>lomitapide<p>valproic acid increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.</p></li><li>mipomersen<p>mipomersen, valproic acid.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.</p></li><li>nateglinide<p>valproic acid will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>oritavancin<p>oritavancin will increase the level or effect of valproic acid by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Oritavancin is a weak CYP2C19 inhibitor; caution if coadministered with CYP2C19 substrates that have a narrow therapeutic index</p></li><li>orlistat<p>orlistat decreases levels of valproic acid by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions.</p></li><li>ospemifene<p>valproic acid, ospemifene.
Either increases levels of the other by plasma protein binding competition. Modify Therapy/Monitor Closely.</p></li><li>parecoxib<p>valproic acid will increase the level or effect of parecoxib by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>phenytoin<p>valproic acid will increase the level or effect of phenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>propofol<p>valproic acid increases effects of propofol by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>rufinamide<p>valproic acid increases levels of rufinamide by decreasing metabolism. Use Caution/Monitor. Initiate rufinamide at a dose &lt;10 mg/kg/day in pediatric patients or &lt;400 mg/day in adults.</p></li><li>secukinumab<p>secukinumab, valproic acid. Other (see comment). Use Caution/Monitor. 
Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, secukinumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of secukinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.</p></li><li>sevelamer<p>sevelamer decreases levels of valproic acid by increasing elimination. Use Caution/Monitor.</p></li><li>teduglutide<p>teduglutide increases levels of valproic acid by sedation. Use Caution/Monitor. Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary.</p></li><li>temozolomide<p>valproic acid increases levels of temozolomide by decreasing metabolism. Use Caution/Monitor. Cautions is advised.</p></li><li>topiramate<p>valproic acid, topiramate.
Either increases toxicity of the other by unknown mechanism. Use Caution/Monitor. Risk of hyperammonemia with or without encephalopathy; pts. with inborn errors of metabolism may be at greater risk.  S/S: altered LOC, lethargy, vomiting.</p></li><li>warfarin<p>valproic acid will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>zidovudine<p>valproic acid increases levels of zidovudine by decreasing metabolism. Use Caution/Monitor. Potential for increased toxicity. .</p></li>